June 3, 2026
Omnipod® 5's 100 mg/dL Target Glucose setting and FreeStyle Libre 3 Plus sensor integration
Omnipod 5 is now even stronger with enhancements designed for more time in range1 and more time in Automated Mode. In this episode, we break down what they are and what they look like in practice.
Hosts Dena Gottesman MS, RD, CDCES and Nancy Hanna RN, BSN, CDE are joined by Dr. Nader Kassam, a pediatric endocrinologist at Corewell Health living with type 1 diabetes, to explore the latest updates coming to Omnipod 5.
Dr. Kassam shares his firsthand experience as a participant of the Limited Market Release of this product. He shares how the new 100 mg/dL Target Glucose setting increases the algorithm’s response to rising glucose levels to help him spend more time in range1 and how these enhancements can help keep users in Automated Mode longer.
The FreeStyle Libre 3 Plus sensor integration results in more personalized care and more real-time glucose monitoring data for caregivers with the LibreLinkUp app.
1. In a simulated analysis, the 100 mg/dL Target Glucose (TG) setting
demonstrated superior Time in Range (70-180 mg/dL) compared with results at the 110-150 mg/dL TG settings in a real-world population of people with T1D using Omnipod 5. Differences in mean TIR for 100mg/dL vs 110mg/dL, vs 120 mg/dL, vs 130 mg/dL, vs 140 mg/dL, vs 150 mg/dL, were 2.5%, 4.8%, 9.8%, 15.3%, and 20.8%, respectively. For each comparison, the lower bound of the one-sided 95% Confidence Interval (CI) was >0%, meeting the pre-specified superiority criterion. Analysis not controlled for ISF, ICR, % time in Automated Mode and number of bolus/day. Data on File. RF-012026-00057.
2:33 – More TIR with the 100mg/dL Target Glucose setting1
6:04 – How adjustable Target Glucose settings support confidence in day-to-day diabetes management
10:30 – Algorithm improvements designed for more time in Automated Mode
14:41 – Sensor choice and how some Libre 3 Plus sensor choice can help families simplify care
1. In a simulated analysis, the 100 mg/dL Target Glucose (TG) setting
demonstrated superior Time in Range (70-180 mg/dL) compared with results at the 110-150 mg/dL TG settings in a real-world population of people with T1D using Omnipod 5. Differences in mean TIR for 100mg/dL vs 110mg/dL, vs 120 mg/dL, vs 130 mg/dL, vs 140 mg/dL, vs 150 mg/dL, were 2.5%, 4.8%, 9.8%, 15.3%, and 20.8%, respectively. For each comparison, the lower bound of the one-sided 95% Confidence Interval (CI) was >0%, meeting the pre-specified superiority criterion. Analysis not controlled for ISF, ICR, % time in Automated Mode and number of bolus/day. Data on File. RF-012026-00057.
Standard additional description for SEO purposes: [MU2] How [MU3] do medical devices like Omnipod 5 improve the lives of people living with diabetes? How can Healthcare Professionals implement Omnipod 5 Automated Insulin Delivery (AID) Systems in practice?
Beyond the Bolus is a US-based diabetes education podcast for healthcare professionals who treat patients living with type 1 (t1d) and type 2 diabetes (t2d).
Hosted by Insulet’s Clincial Services Mangers, Nancy Hanna RN, BSN, CDE, and Dena Gottesman MS, RD, CDCES, this dynamic duo care deeply about helping healthcare professionals (HCP)’s and patients simplify life with
diabetes. Episodes cover a range of topics such as, how to get started with
Omnipod 5 to ongoing care management, helping HCPs make patient conversations more efficient and effective.
Beyond the Bolus also dives into the latest clinical research and data with prominent diabetes experts from across the globe who share real-world experiences and offer insights into what the future of diabetes care could look like with devices like Omnipod 5.
If you’re looking to empower your patients to take back control of their diabetes, then this is the podcast for you.
The Omnipod 5 Automated Insulin Delivery System
is a single hormone insulin delivery system intended to deliver U-100 insulin
subcutaneously for the management of type 1 diabetes in persons aged 2 and older and type 2 diabetes in persons aged 18 and older. Rx only. WARNING: Do not use SmartAdjust™ technology for people under the age of 2 or who require less than 5 U of insulin per day. Visit omnipod.com/safety for complete safety information.
© 2026 Insulet Corporation. All rights reserved.
